S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
Log in
NASDAQ:BCYC

Bicycle Therapeutics Stock Forecast, Price & News

$27.03
+1.53 (+6.00 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$24.72
Now: $27.03
$27.50
50-Day Range
$17.95
MA: $19.61
$25.50
52-Week Range
$10.26
Now: $27.03
$27.50
Volume609,292 shs
Average Volume53,137 shs
Market Capitalization$478.43 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.21
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics plc has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

MarketRank

Overall MarketRank

1.15 out of 5 stars

Medical Sector

771st out of 1,556 stocks

Pharmaceutical Preparations Industry

381st out of 638 stocks

Analyst Opinion: 2.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BCYC
CUSIPN/A
CIKN/A
Phone44-12-2326-1503
Employees81

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.80 million
Book Value$5.27 per share

Profitability

Net Income$-30,610,000.00
Net Margins-321.26%

Miscellaneous

Market Cap$478.43 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable
$27.03
+1.53 (+6.00 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BCYC News and Ratings via Email

Sign-up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bicycle Therapeutics (NASDAQ:BCYC) Frequently Asked Questions

How has Bicycle Therapeutics' stock price been impacted by COVID-19?

Bicycle Therapeutics' stock was trading at $17.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BCYC stock has increased by 52.7% and is now trading at $27.03.
View which stocks have been most impacted by COVID-19
.

Is Bicycle Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bicycle Therapeutics stock.
View analyst ratings for Bicycle Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Bicycle Therapeutics?

Wall Street analysts have given Bicycle Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bicycle Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Bicycle Therapeutics' next earnings date?

Bicycle Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Bicycle Therapeutics
.

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) posted its quarterly earnings data on Thursday, November, 5th. The company reported ($0.52) earnings per share for the quarter, hitting the consensus estimate of ($0.52). The business had revenue of $3.84 million for the quarter, compared to the consensus estimate of $1.05 million. Bicycle Therapeutics had a negative net margin of 321.26% and a negative return on equity of 42.73%.
View Bicycle Therapeutics' earnings history
.

What price target have analysts set for BCYC?

4 brokerages have issued 12-month price objectives for Bicycle Therapeutics' shares. Their forecasts range from $25.00 to $38.00. On average, they expect Bicycle Therapeutics' share price to reach $31.00 in the next year. This suggests a possible upside of 14.7% from the stock's current price.
View analysts' price targets for Bicycle Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Bicycle Therapeutics' key competitors?

What other stocks do shareholders of Bicycle Therapeutics own?

Who are Bicycle Therapeutics' key executives?

Bicycle Therapeutics' management team includes the following people:
  • Dr. Kevin Lee M.B.A., Ph.D., CEO & Exec. Director (Age 51, Pay $1.01M)
  • Mr. Lee H. Kalowski, Pres & CFO (Age 39, Pay $654.18k)
  • Sir Gregory Paul Winter, Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board (Age 69, Pay $23.95k)
  • Dr. Michael Skynner Ph.D., B.sc. Ph.d., Chief Operating Officer (Age 51, Pay $626.03k)
  • Mr. Christian Heinis, Scientific Founder
  • Dr. Nicholas Keen, Chief Scientific Officer (Age 52)
  • Mr. Zafar Qadir, Gen. Counsel
  • Dr. Gillian Langford Ph.D., Head of Clinical and Project Management
  • Ms. Rosamond Deegan, Pres of U.S. and Chief Bus. Officer of U.S. (Age 48)
  • Dr. Phil Jeffrey, Sr. VP of Pre-Clinical Devel.

When did Bicycle Therapeutics IPO?

(BCYC) raised $64 million in an IPO on Thursday, May 23rd 2019. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Bicycle Therapeutics' stock symbol?

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bicycle Therapeutics' stock price today?

One share of BCYC stock can currently be purchased for approximately $27.03.

How big of a company is Bicycle Therapeutics?

Bicycle Therapeutics has a market capitalization of $478.43 million and generates $13.80 million in revenue each year. The company earns $-30,610,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis. Bicycle Therapeutics employs 81 workers across the globe.

What is Bicycle Therapeutics' official website?

The official website for Bicycle Therapeutics is www.bicycletherapeutics.com.

How can I contact Bicycle Therapeutics?

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company can be reached via phone at 44-12-2326-1503.

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.